Search

Introduction: The application of single-cell RNA sequencing has greatly improved our understanding of various cellular and molecular mechanisms involved in physiological and pathophysiological processes. However, obtaining living cells for this technique can be difficult under certain conditions. To solve this problem, the methanol fixation method appeared as a promising alternative for routine clinical use. Materials and Methods: In this study, we selected two AML samples that had been fixed in methanol for 12–18 months. Once the cells were rehydrated, these samples were subjected to single-cell RNA sequencing. We then compared the results obtained from these samples with those obtained from the same samples cryopreserved in DMSO. Results: We used a previously validated methanol fixation protocol to perform scRNA-seq on DMSO cryopreserved cells and cells fixed in methanol for more than one year. Preliminary results show that methanol fixation induces some genetic and transcriptional modification compared with DMSO cryopreservation but remains a valuable method for single-cell analysis of primary human leukemia cells. Conclusions: The initial findings from this study highlight certain resemblances in methanol fixation over a 12-month period and cryopreservation with DMSO, along with associated transcriptional level modifications. However, we observed genetic degradation in the fixation condition when extending beyond one year. Despite certain study limitations, it is evident that short-term methanol fixation can be effectively used for leukemia blast samples. Its ease of implementation holds the potential to simplify the integration of this technique into routine clinical practice. [ABSTRACT FROM AUTHOR]

Decades ago, the treatment for acute myeloid leukemia relied on cytarabine and anthracycline. However, advancements in medical research have introduced targeted therapies, initially employing monoclonal antibodies such as ant-CD52 and anti-CD123, and subsequently utilizing specific inhibitors that target molecular mutations like anti-IDH1, IDH2, or FLT3. The challenge lies in determining the role of these therapeutic options, considering the inherent tumor heterogeneity associated with leukemia diagnosis and the clonal drift that this type of tumor can undergo. Targeted drugs necessitate an examination of various therapeutic targets at the individual cell level rather than assessing the entire population. It is crucial to differentiate between the prognostic value and therapeutic potential of a specific molecular target, depending on whether it is found in a terminally differentiated cell with limited proliferative potential or a stem cell with robust capabilities for both proliferation and self-renewal. However, this cell-by-cell analysis is accompanied by several challenges. Firstly, the scientific aspect poses difficulties in comparing different single cell analysis experiments despite efforts to standardize the results through various techniques. Secondly, there are practical obstacles as each individual cell experiment incurs significant financial costs and consumes a substantial amount of time. A viable solution lies in the ability to process multiple samples simultaneously, which is a distinctive feature of the cell hashing technique. In this study, we demonstrate the applicability of the cell hashing technique for analyzing acute myeloid leukemia cells. By comparing it to standard single cell analysis, we establish a strong correlation in various parameters such as quality control, gene expression, and the analysis of leukemic blast markers in patients. Consequently, this technique holds the potential to become an integral part of the biological assessment of acute myeloid leukemia, contributing to the personalized and optimized management of the disease, particularly in the context of employing targeted therapies. [ABSTRACT FROM AUTHOR]

Different epithelia line the body and organs and form a continuous lining of cells. The junction of two different types of epithelia represents a special region called transition zone (TZ). TZ are small areas found in numerous places in the body such as between the esophagus and the stomach, in the cervix, in the eye, and between the anal canal and the rectum. These zones are associated with diverse pathologies such as cancers; however, the cellular and molecular mechanisms involved in tumor progression are poorly investigated. We recently characterized the role of anorectal TZ cells during homeostasis and after injury using an in vivo (lineage tracing) approach. To follow TZ cells, we previously developed a mouse model of lineage tracing using cytokeratin 17 (Krt17) as a promoter and GFP as a reporter. Krt17 is expressed by TZ but also by anal glands located below the TZ in the stroma that can interfere with TZ cell population isolation and analysis afterward. In this chapter, we provide a new dissection method to remove specifically anal glands without affecting anorectal TZ cells. This protocol allows the specific dissection and isolation of anal canal, TZ, and rectum epithelia., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Special regions called transition zones (TZs) are found at numerous places in the body. TZs represent the junction between two different types of epithelia and are located between the esophagus and the stomach, in the cervix, in the eye, and between the anal canal and the rectum. TZ is a heterogeneous population, and the detailed characterization of its populations requires an analysis at the single-cell level. In this chapter, we provide a protocol to do single-cell RNA sequencing primary analysis of anal canal, TZ, and rectum epithelia., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)